Neoadjuvant GOLP Prolongs EFS Among Patients with Resectable High-Risk Intrahepatic Cholangiocarcinoma
esmo - Findings from the ZSAB-neoGOLP study
AI Summary: The ZSAB‑neoGOLP trial shows that giving a four‑drug neoadjuvant regimen—gemcitabine, oxaliplatin, lenvatinib and toripalimab—before surgery prolongs event‑free survival for patients with resectable, high‑risk intrahepatic cholangiocarcinoma. The finding suggests preoperative systemic therapy can downstage aggressive tumors and delay recurrence, potentially changing treatment sequencing for this challenging disease.
Related Stories
ENZAMET trial confirms long-term survival benefit of enzalutamide in mHSPC / 8 days
Nine‑year CheckMate‑214 follow‑up confirms durable immunotherapy benefit / 1 month
Teclistamab shows survival benefit prompting earlier use discussions / 2 months
CAR-PRISM trial shows BCMA CAR T effective in high-risk smoldering myeloma / 4 months
Long‑term immunotherapy appears safe for alveolar soft part sarcoma / 4 months
Zongertinib emerges as first-line therapy for HER2‑mutant NSCLC / 4 months
Antoni Ribas receives AACR‑Margaret Foti Award for leadership / 4 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Mergers and Acquisitions, Biotech, Pfizer, Reproductive Health and look for the RSS link.
StackHealth Time Machine